These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18548196)

  • 1. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.
    Zver S; Zadnik V; Černelč P; Koželj M
    Int J Hematol; 2008 Sep; 88(2):227-236. PubMed ID: 18548196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    Zver S; Zadnik V; Bunc M; Rogel P; Cernelc P; Kozelj M
    Int J Hematol; 2007 Jun; 85(5):408-14. PubMed ID: 17562616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.
    Kozelj M; Zver S; Zadnik V
    Radiol Oncol; 2013 Jun; 47(2):161-5. PubMed ID: 23801913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide.
    Snowden JA; Hill GR; Hunt P; Carnoutsos S; Spearing RL; Espiner E; Hart DN
    Bone Marrow Transplant; 2000 Aug; 26(3):309-13. PubMed ID: 10967571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
    Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
    Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.
    Palumbo A; Pileri A; Triolo S; Omedè P; Bruno B; Ciravegna G; Galliano M; Frieri R; Boccadoro M
    Bone Marrow Transplant; 1997 Jan; 19(1):23-9. PubMed ID: 9012927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors].
    Benvenuto GM; La Vecchia L; Morandi P; Ruffini P; Mezzena G
    Ital Heart J Suppl; 2000 Nov; 1(11):1457-63. PubMed ID: 11109196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Lin CJ; Vader JM; Slade M; DiPersio JF; Westervelt P; Romee R
    Cancer; 2017 May; 123(10):1800-1809. PubMed ID: 28262921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
    Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years.
    Kulkarni S; Powles R; Treleaven J; Singhal S; Horton C; Sirohi B; Bhagawati N; Tait D; Saso R; Killick S; Pinkerton R; Atra A; Meller S; Mehta J
    Bone Marrow Transplant; 2000 Feb; 25(4):365-70. PubMed ID: 10723578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide.
    Morandi P; Ruffini PA; Benvenuto GM; La Vecchia L; Mezzena G; Raimondi R
    Bone Marrow Transplant; 2001 Aug; 28(3):277-82. PubMed ID: 11535996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
    Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
    Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
    Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Vuolteenaho O; Ala-Kopsala M; Nousiainen T; Hartikainen J
    Eur J Haematol; 2006 Aug; 77(2):120-7. PubMed ID: 16856907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.